Results 91 to 100 of about 612,327 (210)

Putative cutaneous adverse drug reactions in two dogs

Veterinary Record Case Reports, Volume 14, Issue 4, November 2026.
Summary We describe two cases of cutaneous adverse drug reactions (CADR) in dogs. Case 1 presented with erythematous macules with sharply demarcated margins on the abdomen and inguinal area and depigmentation on the lip. Skin lesions appeared after 3 weeks of administration of anti‐epileptic drugs, including phenobarbital.
Je‐Seong Kwon, Dong‐ho Noh, Daekyung Kim, Jinho Park, Ji‐Seon Yoon   +4 more
wiley   +1 more source

TOXIC EPIDERMAL NECROLYSIS (LYELL’S SYNDROME)

Журнал инфектологии, 2018
.
E. N. Kudelka, D. M. Shakhmanov, A. F. Sobolev, R. A. Ravodin, A. V. Chaplygin, M. V. Gusarov, S. S. Yakushenko   +6 more
doaj   +1 more source

Dermatologic Toxicities Associated With Novel Pan‐RAS/RAF Inhibitors

Journal of Cutaneous Pathology, Volume 53, Issue 11, Page 1042-1050, November 2026.
ABSTRACT Background The mitogen‐activated protein kinase (MAPK) pathway plays a key role in cell‐cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan‐RAS (RMC‐6236) and pan‐RAF (LXH254/naporafenib) inhibitors are emerging.
Lin J. He, Shaymaa Hegazy, Phyu P. Aung, Priyadharsini Nagarajan, Fiorinda Muhaj, Adrienne N. Choksi, Ana M. Ciurea, Kelly C. Nelson, Doina Ivan, Carlos A. Torres‐ Cabala, Victor G. Prieto, Jonathan L. Curry   +11 more
wiley   +1 more source

A case report of toxic epidermal necrolysis associated with AZD-9291

, 2018
Jie Wang, XianYe Cheng, Yan Lu, BingRong Zhou Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, The People’s Republic of China Abstract: Epidermal growth factor receptor-tyrosine kinase ...
Cheng XY, Lu Y, Zhou BR, Wang J
core  

Adverse Reactions Identified after Approval of Novel Medicines: Analysis of 339 New Molecular Entities and Therapeutic Biologics

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1120-1128, October 2026.
Postmarketing safety surveillance data identify safety issues not identified in preapproval clinical trials. We describe the frequency of new safety issues overall and by labeling section and the relationship of the most commonly added safety issues with the cumulative number of prescriptions dispensed via retail pharmacies.
Ellen Pinnow, Brendan Day, Esther H. Zhou, Corinne Woods, Nana Dwumfour, Jenni Y. Lee, Ilynn Bulatao, Sanae Cherkaoui, Manish Kalaria, Sonja Brajovic, Nabila Sadiq, Farideh Sistani, Maggie Lee, Grace Chai, Gerald Dal Pan   +14 more
wiley   +1 more source

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS).
Clare J. Rowntree, Amy A. Kirkwood, Nadine Farah, Emma Lawrie, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Anthony V. Moorman, Bela Patel, Pip Patrick, Paul Smith, Krisztina Z. Alapi, Lingyi Wang, Marc R. Mansour, Adele K. Fielding   +14 more
wiley   +1 more source

A Seven‐Year Retrospective Study on the Epidemiology of Cutaneous Adverse Drug Reactions in Hospitalized Patients From Southern Iran: A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Introduction Cutaneous adverse drug reactions (CADRs) represent a significant clinical challenge, ranging from mild to life‐threatening conditions such as Stevens‐Johnson syndrome (SJS) and toxic epidermal necrosis (TEN). This study aims to evaluate the epidemiological and clinical characteristics of CADRs in patients admitted to a tertiary ...
Mohammadreza Keshtkar, Fatemeh Hemmati, Yasamin Dehghan, Fatemeh Kiani, Mohammad Ali Salimi, Negin Fazelzadeh Haghighi   +5 more
wiley   +1 more source

Empirical Meropenem Versus Piperacillin/Tazobactam for Critically Ill Adults With Sepsis: Feasibility of a Randomised Trial

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 9, October 2026.
ABSTRACT Background Meropenem and piperacillin/tazobactam are commonly used empirical antibiotics in critically ill adults with sepsis, but whether one is superior to the other is uncertain. Methods The Empirical Meropenem versus Piperacillin/Tazobactam for Adult Patients with Sepsis (EMPRESS) trial is an ongoing investigator‐initiated, randomised ...
Nick Frørup Meier, Morten Hylander Møller, Maj‐Brit Nørregaard Kjær, Fredrik Sjövall, Marie Warrer Munch, Benjamin Skov Kaas‐Hansen, Hans‐Christian Thorsen‐Meyer, Bodil Steen Rasmussen, Marie Helleberg, Frederik Boëtius Hertz, Theis Lange, Aksel Karl Georg Jensen, Lars Wiuff Andersen, Jakob Steen Andersen, Jens Michelsen, Lars Peter Kloster Andersen, Morten Heiberg Bestle, Anne Craveiro Brøchner, Theis Skovsgaard Itenov, Steffen Christensen, Ronni Thermann Reitz Plovsing, Klaus Ulrik Koch, Anders Møller, Olav Lilleholt Schjørring, Naia Bech Cranø, Kasper Vamdrup‐Andersen, Davide Placido, Tine Sylvest Meyhoff, Carl Thomas Anthon, Aske Tøgern, Milda Grigonyte‐Daraskeviciene, Zemira Engbakken, Anne Witte Kamstrup, Kis Rønn Uhre, Jehad Ahmad Barakji, Rikke Faebo Larsen, Anders Perner, Anders Granholm   +37 more
wiley   +1 more source

INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol

BJU International, Volume 138, Issue 4, Page 607-619, October 2026.
Background High‐risk non‐muscle‐invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette–Guérin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease.
Ruby Lister‐Whelan, Ethan Senior, Jessica Kendall, Jamie B. Oughton, Fiona Collinson, Jon Griffin, Rachel Hubbard, Steven Kennish, Aidan Noon, Derek J. Rosario, Irbaz B. Riaz, Julie Telliez, James W. F. Catto, Syed A. Hussain   +13 more
wiley   +1 more source

Results of treatment in our patients with toxic epidermal necrolysis [PDF]

, 2014
Objective: Toxic epidermal necrolysis is a rare disease that has very high mortality and morbidity. Despite the high mortality rate of the disease, treatment is still controversial today.
Ozturk, Fadil, Paksu, Sukru, Sancak, Recep, Sogut, Ayhan, Gusner, Sukru Nail, Celiksoy, Mehmet Halil   +5 more
core   +1 more source